CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Consensus Rating of “Moderate Buy” from Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $8.60.

Several research analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Leerink Partners boosted their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd.

CAMP4 Therapeutics Trading Up 2.8%

Shares of NASDAQ CAMP opened at $4.46 on Friday. The company has a market cap of $231.61 million, a price-to-earnings ratio of -1.89 and a beta of 0.04. CAMP4 Therapeutics has a 12 month low of $1.30 and a 12 month high of $7.75. The stock has a 50-day moving average price of $4.63 and a two-hundred day moving average price of $4.61.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 176.90% and a negative net margin of 2,193.72%. On average, sell-side analysts predict that CAMP4 Therapeutics will post -0.78 earnings per share for the current year.

Institutional Trading of CAMP4 Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $70,000. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $86,000. OMERS ADMINISTRATION Corp bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $115,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.